# Biox-Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biox-vision

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.biox-vision.com
- Latest round: Series A (Jul 6, 2017)
- Investors on record: 2

## About

Founded in 2013 and based in Hefei, China, Biox-Vision operates as a biotechnology company that focuses on antigen and antibody R&D and application services. It was recognized as the National High-tech Enterprise. The company has 4 branch offices. In July 2017, Biox-Vision closed a series A funding. It acquired the Medical Device Business License in 2019.

Biox-Vision's main business is antigen and antibody research and development and application services. Its main products are tumor antibody drugs, including monoclonal antibody PD1 monoclonal antibody, anti-PD1-anti-CD40 antibody, etc. The PD1 antibody-directed targeted therapy developed by it can alleviate the pain caused by radiotherapy and chemotherapy to cancer patients. The company also provides rapid test kits, folate receptor test kits and other test kits.

The company generates revenue by providing antibody R&D and application services.

## Funding rounds

- Series A, Jul 6, 2017 — Hefei High-tech Venture Capital, Shenzhen Qianhai Ruixinda Investment
- Angel, Apr 15, 2015 — Hefei High-tech Venture Capital

## Investors

- Hefei High-tech Venture Capital (https://capitalatlas.ai/funds/hefei-high-tech-venture-capital) — Angel, Series A
- Shenzhen Qianhai Ruixinda Investment — Series A